Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma

Àgnes Bánkfalvi, K. Tory, Mechthild Kemper, Dirk Breukelmann, Christiane Cubick, Christopher Poremba, László Füzesi, Ralph J. Lellè, Werner Böcker

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The present study was designed to investigate the clinical/prognostic relevance of immunohistochemical expression of p53-targeted genes mdm-2, p21(WAF1) and bcl-2 alone and in combination with p53 for the indirect assessment of p53 gene status in breast cancer. 141 archival breast carcinomas were immunostained, and the putative mutational status of the p53 gene was defined in 21 of them, as a control for immunohistochemistry, using the polymerase chain reaction single-strand conformational polymorphism (PCR- SSCP) analysis. Genetic changes of p53 correlated significantly with p53 protein overexpression (p = 0.01) but did not do so with any of the related molecules. Immunohistochemical p53 status was directly correlated with mdm-2 (p = 0.0001), p21 (p = 0.0004) and inversely with bcl-2 (p = 0.005) expression, bcl-2 proved to be an independent marker of prognosis, p53 only in the group of node-positive carcinomas, whereas bcl-2-/p53+ tumours revealed the worst prognosis. Mdm-2 and p21 expression was of prognostic significance neither alone nor in combination. We conclude that the detection of downstream regulators of p53 does not increase the efficacy of immunohistochemistry in assessing the functional status of p53 in breast cancer; however, their combined analysis may help to select subgroups of patients at the extremes of risk for recurrence, or those with greater chances for survival.

Original languageEnglish
Pages (from-to)489-501
Number of pages13
JournalPathology Research and Practice
Volume196
Issue number7
Publication statusPublished - 2000

Fingerprint

p53 Genes
Breast Neoplasms
Immunohistochemistry
Carcinoma
Recurrence
Polymerase Chain Reaction
Survival
Neoplasms
Proteins

Keywords

  • bcl-2
  • Breast cancer
  • Immunohistochemistry
  • Mdm-2
  • p21
  • p53
  • PCR-SSCP
  • Survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Bánkfalvi, À., Tory, K., Kemper, M., Breukelmann, D., Cubick, C., Poremba, C., ... Böcker, W. (2000). Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. Pathology Research and Practice, 196(7), 489-501.

Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. / Bánkfalvi, Àgnes; Tory, K.; Kemper, Mechthild; Breukelmann, Dirk; Cubick, Christiane; Poremba, Christopher; Füzesi, László; Lellè, Ralph J.; Böcker, Werner.

In: Pathology Research and Practice, Vol. 196, No. 7, 2000, p. 489-501.

Research output: Contribution to journalArticle

Bánkfalvi, À, Tory, K, Kemper, M, Breukelmann, D, Cubick, C, Poremba, C, Füzesi, L, Lellè, RJ & Böcker, W 2000, 'Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma', Pathology Research and Practice, vol. 196, no. 7, pp. 489-501.
Bánkfalvi, Àgnes ; Tory, K. ; Kemper, Mechthild ; Breukelmann, Dirk ; Cubick, Christiane ; Poremba, Christopher ; Füzesi, László ; Lellè, Ralph J. ; Böcker, Werner. / Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. In: Pathology Research and Practice. 2000 ; Vol. 196, No. 7. pp. 489-501.
@article{beefeb91445640d78884d7e74dc55e8c,
title = "Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma",
abstract = "The present study was designed to investigate the clinical/prognostic relevance of immunohistochemical expression of p53-targeted genes mdm-2, p21(WAF1) and bcl-2 alone and in combination with p53 for the indirect assessment of p53 gene status in breast cancer. 141 archival breast carcinomas were immunostained, and the putative mutational status of the p53 gene was defined in 21 of them, as a control for immunohistochemistry, using the polymerase chain reaction single-strand conformational polymorphism (PCR- SSCP) analysis. Genetic changes of p53 correlated significantly with p53 protein overexpression (p = 0.01) but did not do so with any of the related molecules. Immunohistochemical p53 status was directly correlated with mdm-2 (p = 0.0001), p21 (p = 0.0004) and inversely with bcl-2 (p = 0.005) expression, bcl-2 proved to be an independent marker of prognosis, p53 only in the group of node-positive carcinomas, whereas bcl-2-/p53+ tumours revealed the worst prognosis. Mdm-2 and p21 expression was of prognostic significance neither alone nor in combination. We conclude that the detection of downstream regulators of p53 does not increase the efficacy of immunohistochemistry in assessing the functional status of p53 in breast cancer; however, their combined analysis may help to select subgroups of patients at the extremes of risk for recurrence, or those with greater chances for survival.",
keywords = "bcl-2, Breast cancer, Immunohistochemistry, Mdm-2, p21, p53, PCR-SSCP, Survival",
author = "{\`A}gnes B{\'a}nkfalvi and K. Tory and Mechthild Kemper and Dirk Breukelmann and Christiane Cubick and Christopher Poremba and L{\'a}szl{\'o} F{\"u}zesi and Lell{\`e}, {Ralph J.} and Werner B{\"o}cker",
year = "2000",
language = "English",
volume = "196",
pages = "489--501",
journal = "Pathology Research and Practice",
issn = "0344-0338",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "7",

}

TY - JOUR

T1 - Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma

AU - Bánkfalvi, Àgnes

AU - Tory, K.

AU - Kemper, Mechthild

AU - Breukelmann, Dirk

AU - Cubick, Christiane

AU - Poremba, Christopher

AU - Füzesi, László

AU - Lellè, Ralph J.

AU - Böcker, Werner

PY - 2000

Y1 - 2000

N2 - The present study was designed to investigate the clinical/prognostic relevance of immunohistochemical expression of p53-targeted genes mdm-2, p21(WAF1) and bcl-2 alone and in combination with p53 for the indirect assessment of p53 gene status in breast cancer. 141 archival breast carcinomas were immunostained, and the putative mutational status of the p53 gene was defined in 21 of them, as a control for immunohistochemistry, using the polymerase chain reaction single-strand conformational polymorphism (PCR- SSCP) analysis. Genetic changes of p53 correlated significantly with p53 protein overexpression (p = 0.01) but did not do so with any of the related molecules. Immunohistochemical p53 status was directly correlated with mdm-2 (p = 0.0001), p21 (p = 0.0004) and inversely with bcl-2 (p = 0.005) expression, bcl-2 proved to be an independent marker of prognosis, p53 only in the group of node-positive carcinomas, whereas bcl-2-/p53+ tumours revealed the worst prognosis. Mdm-2 and p21 expression was of prognostic significance neither alone nor in combination. We conclude that the detection of downstream regulators of p53 does not increase the efficacy of immunohistochemistry in assessing the functional status of p53 in breast cancer; however, their combined analysis may help to select subgroups of patients at the extremes of risk for recurrence, or those with greater chances for survival.

AB - The present study was designed to investigate the clinical/prognostic relevance of immunohistochemical expression of p53-targeted genes mdm-2, p21(WAF1) and bcl-2 alone and in combination with p53 for the indirect assessment of p53 gene status in breast cancer. 141 archival breast carcinomas were immunostained, and the putative mutational status of the p53 gene was defined in 21 of them, as a control for immunohistochemistry, using the polymerase chain reaction single-strand conformational polymorphism (PCR- SSCP) analysis. Genetic changes of p53 correlated significantly with p53 protein overexpression (p = 0.01) but did not do so with any of the related molecules. Immunohistochemical p53 status was directly correlated with mdm-2 (p = 0.0001), p21 (p = 0.0004) and inversely with bcl-2 (p = 0.005) expression, bcl-2 proved to be an independent marker of prognosis, p53 only in the group of node-positive carcinomas, whereas bcl-2-/p53+ tumours revealed the worst prognosis. Mdm-2 and p21 expression was of prognostic significance neither alone nor in combination. We conclude that the detection of downstream regulators of p53 does not increase the efficacy of immunohistochemistry in assessing the functional status of p53 in breast cancer; however, their combined analysis may help to select subgroups of patients at the extremes of risk for recurrence, or those with greater chances for survival.

KW - bcl-2

KW - Breast cancer

KW - Immunohistochemistry

KW - Mdm-2

KW - p21

KW - p53

KW - PCR-SSCP

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0343628888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343628888&partnerID=8YFLogxK

M3 - Article

VL - 196

SP - 489

EP - 501

JO - Pathology Research and Practice

JF - Pathology Research and Practice

SN - 0344-0338

IS - 7

ER -